Intra-Cellular Therapies Inc
(BSP:I2TC34)
R$
83.36
0 (0%)
Market Cap: 53.03 Bil
Enterprise Value: 47.40 Bil
PE Ratio: 0
PB Ratio: 8.38
GF Score: 41/100 
Intra-Cellular Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021 / 05:20PM GMT
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Good afternoon, everyone. Welcome to the 1:20 session here on Day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover European and U.S. biopharmaceutical names for the firm. It's my great pleasure to be hosting Intra-Cellular Therapies today in a fireside chat session. And with that, from the company, we've got CEO, Sharon Mates; and Chief Commercialization Officer, Mark Neumann, joining us. Sharon and Mark, it's great to see you, both, welcome to the conference.
Sharon Mates
Intra-Cellular Therapies, Inc. - Co-Founder, Chairman, CEO & President
Thanks, Graig. It's a pleasure to be here.
Mark Neumann;Graig Suvannavejh
Intra-Cellular Therapies, Inc. - EVP & Chief Commercial Officer;Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Thank you, Graig.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers